9-month overall survival was 43 % ( 95 % CI 29-57 ) in the lomustine group , 38 % ( 25-51 ) in the bevacizumab group , 59 % ( 43-72 ) in the bevacizumab and lomustine 90 mg/m ( 2 ) group , 87 % ( 39-98 ) in the bevacizumab and lomustine 110 mg/m ( 2 ) group , and 63 % ( 49-75 ) for the combined bevacizumab and lomustine groups .